Shares of Pfizer Inc and U.S.-listed shares of partner BioNTech SE rose on Friday after they released additional data for their experimental coronavirus vaccine and reiterated they were on track to seek a regulatory review in October.
Pfizer, BioNTech shares gain as more data backs vaccine candidate
